Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report

Private equity giant Blackstone Inc. BX is reportedly close to finalizing a deal to sell Alinamin Pharmaceutical, a Japanese supplement maker, to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion).

The agreement is anticipated to be finalized shortly, reported Reuters, citing a person familiar with the matter.

Also Read: Private Equity Giant Blackstone Targets Japanese Market, Anticipates ‘Accelerated Growth’: Report

According to the Nikkei, MBK plans to leverage its expertise in consumer goods acquisitions to enhance Alinamin’s value. Following the Blackstone deal, the company established a unit in Taiwan and expanded its international sales efforts.

Last month, Blackstone stated it is collaborating with financial advisers on a potential sale of Tokyo-based Alinamin, which could be valued at roughly ¥300 billion ($1.9 billion).

Notably, Blackstone acquired Alinamin from Takeda Pharmaceutical Company TAK in 2020.

Recently, the company reportedly agreed to purchase a 55.1% stake in Japanese e-comics provider Infocom Corp. for about ¥260 billion ($1.66 billion).

Blackstone stock has gained more than 29% in the last 12 months. Investors can gain exposure to the stock via Invesco Global Listed Private Equity ETF PSP and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF LBO.

Price Action: BX shares are down 0.60% at $121.50 premarket at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Image via Shutterstock